Dr. Rene Hoet

René Hoet is extraordinary Professor Biopharmaceutics at the University of Maastricht, Netherlands, guiding researchers to use antibodies to bridge the gap between academic research and pharmaceutical applications.

Since April 1 2021 Rene works as Chief Scientific Officer at Montis Biosciences, Leuven, Belgium to develop the next generation Immuno-Oncology drugs using a novel approach interfering in the Tumor Endothelial Cell and Perivascular Macrophage Interactions to restore a immunocompetent tumor microenvironment.

Prior to this he worked as Chief Scientific Officer for Imcheck Therapeutics (Oct 2018- April 2021) developing the first gamma delta T cell activating antibody from preclinical stage into the clinic. Before joining ImCheck, René spent 8 years at Bayer AG as Vice President Biologics Research, where his team was responsible for antibody lead discovery and optimization developing multiple antibodies from discovery into the clinic in Hematology, Cardiology, Gynecology, Immuno-Oncology and Autoimmunity. Between 2008-2010, he was a member of the management team at Genmab and as Senior Director Research led the team Product Related Research, Scientific Communication & Translational Research. Together with his team, he ran the antibody discovery programs and actively supported Genmab’s clinical antibody programs. René started his industrial career at Target Quest (acquired by Dyax in 1999) where his last position was Vice President Research and Operational Manager of Dyax SA. He was the driving force for internal antibody lead discovery as well as external collaborations and supported the out-licensing of Dyax’ antibody phage libraries. From these libraries, 4 antibodies have been approved by the FDA & EMA and over 10 antibodies from varies companies are currently in clinical trials.